About Us
Cancer that spreads to the brain has almost nothing that works. Most cancer drugs never get there at all.
The blood-brain barrier keeps them out. Reglagene was built to get one through: a therapy that works on the primary tumor and on the metastases, including in the brain.
How Reglagene started
In November 2016, Richard Austin, formerly of Sanofi and GSK, sat down with Laurence Hurley and Vijay Gokhale at the University of Arizona. No meaningful new therapy had been approved for the deadliest brain cancers since 1999. They founded Reglagene to change that.
What we are building
Reglagene is focused on a single asset. RGN6024 is an oral, brain-penetrant small molecule that targets tubulin, a mechanism validated across many solid tumors but never made to work in the brain. We run lean, with a small internal team working alongside CRO and academic partners.
Where we are
RGN6024 has completed pharmacology, tolerability studies in two species, and GMP manufacturing process development. It holds FDA Orphan Drug Designation.
Two primary things stand between RGN6024 and an IND: GLP toxicology and GMP manufacture.
Meet the Team
Management
“It’s a great honor to lead a team of incredibly talented individuals who share the vision of developing next-generation CNS oncology therapies. It’s never easy to bring ideas from concept into the clinic. But with the right team, a lot of perseverance, and taking a leap into something once thought impossible, you can change the world.” —Richard Austin, Chief Executive Officer
Richard Austin, PhD, MBA
Chief Executive Officer/President/Co-Founder
Vijay Gokhale, PhD
Co-Founder
Board
Reglagene's board blends pharmaceutical industry professionals with track records of delivering drug development programs and operations management with scientist–managers possessing a full command of the technology and its applications.
Lawrence Kinet, MBA
Board Chair
Laurence Hurley, PhD
Director/Co-Founder
Sharon Ayd, PhD, MBA
Director
Richard Austin, PhD, MBA
Director
CEO/President
Jeffrey Lang
Director
Advisors
Reglagene is advised by drug discovery and development professionals with exceptional track records of advancing new cancer medicines into the clinic and onto the market
Vinton Cheng, MBBS, DPhil
University of Birmingham
Sudhir Manda, MD, FACP
Arizona Oncology